Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celleration Inc.

This article was originally published in Start Up

Executive Summary

There are four pillars of chronic wound care, and few products address all of them satisfactorily. The four factors encouraging wound healing include debridement, bacterial management, increased blood circulation, and the stimulation of healthy cells. Celleration believes it has all four requirements covered with its MIST Therapy System ultrasound device for wound healing.

You may also be interested in...



Advanced Wound Care: The Device Industry's New Billion Dollar Product Market

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (This article also appeared as "Wound Care: Medtech's New Billion Dollar Product Market," Medtech Insight November/December 2007)

Wound Care: Medtech's New Billion Dollar Product Market

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (A Reprint of "Advanced Wound Care: The Device Industry's Billion Dollar Product Market," appearing in START-UP, November 2007.

Salve for the Wound Care Market

Wound care, once known as an investment graveyard, is changing. An advanced wound care market that once focused high-end technology on the small and difficult market of burns has now recognized an opportunity in chronic wounds, an enormous and growing market driven by the demographics of aging, and that segment has recently witnessed a dramatic success story. In 2004, the most successful medical device IPO was that of wound care company Kinetic Concepts.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel